Open Orphan Plc ( (GB:HVO) ) has issued an update.
hVIVO plc has announced the release of its final results for the year ended 31 December 2024, scheduled for 10 April 2025. The announcement includes an analyst briefing and an investor presentation, which will be led by CEO Yamin ‘Mo’ Khan and CFO Stephen Pinkerton. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
More about Open Orphan Plc
hVIVO plc is a rapidly growing early-stage Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including seven of the world’s ten largest biopharma companies. Specializing in human challenge trials for infectious and respiratory diseases, hVIVO operates the largest quarantine facility in London and offers virology and immunology laboratory services under the hLAB brand. It also runs a 120-bed capacity through its German subsidiary, CRS, and offers drug development consulting and biometry services via Venn Life Sciences.
YTD Price Performance: -24.39%
Average Trading Volume: 3,180,834
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £105.8M
For an in-depth examination of HVO stock, go to TipRanks’ Stock Analysis page.